Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The fifth Myeloma Meeting was held in San Diego, CA, and took place on 7–9 September, 2018. The Myeloma Meeting provides an opportunity for research leaders in the field of myeloma to discuss clinical advances in myeloma, in order to further our understanding of recent advances in myeloma, and to encourage interactive discussion. A key focus is the clinical management of myeloma. Highlights from this year's Myeloma Meeting include defining the genomics of myeloma in the development of novel targets, immune-based therapies such as CAR T-cell therapy, and utilizing measurable residual disease (MRD) as a prognostic indicator.

iwMyeloma 2018

07–09 September 2018 | San Diego, CA

iwMyeloma 2018

07–09 September 2018 | San Diego, CA
The fifth Myeloma Meeting was held in San Diego, CA, and took place on 7–9 September, 2018. The Myeloma Meeting provides an opportunity for research leaders in the field of myeloma to discuss clinical advances in myeloma, in order to further our understanding of recent advances in myeloma, and to encourage interactive discussion. A key focus is the clinical management of myeloma. Highlights from this year's Myeloma Meeting include defining the genomics of myeloma in the development of novel targets, immune-based therapies such as CAR T-cell therapy, and utilizing measurable residual disease (MRD) as a prognostic indicator.